Surmodics, Inc.

As of June 30, 2025, Surmodics, Inc. has 14.30M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 3.50, and the price-to-book ratio stands at 6.80.

As of June 30, 2025, Surmodics, Inc. trades at an EV/EBITDA multiple of 1,063.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Surmodics, Inc. trades at an EV/FCF ratio of 106.75, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Surmodics, Inc. maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.27, indicating elevated leverage, while an interest coverage ratio of -1.11 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Surmodics, Inc. posted a negative return on equity (ROE) of -24.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.15, reflecting losses generated across the asset base. Inventory turnover of 4.31 indicates how many times Surmodics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 28, 2025, Surmodics, Inc.'s stock has gained approximately 8.70% over the past 52 weeks. The 50-day moving average sits at 32.20, while the 200-day moving average is 31.44.

Over the twelve months ended June 30, 2025, Surmodics, Inc. posted a gross margin of 44.46, reflecting its pricing power and cost economics. The operating margin of -10.22 and net profit margin of -14.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -0.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Surmodics, Inc. shareholders.

Surmodics, Inc.'s most recent stock split took place on December 7, 2000 with a 1:2 split ratio.

As of June 30, 2025, Surmodics, Inc. has an Altman Z-Score of 6.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.